Kuros Biosciences announces favorable preliminary results of MagnetOs as standalone alternative to autograft in first randomized controlled trial
Schlieren (Zurich), Switzerland, May 31, 2022 – Kuros Biosciences (“Kuros” or the “Company”), a leader in next generation bone graft technologies, announced today promising preliminary results from the first of its five planned randomized controlled trials for its MagnetOs family, comparing MagnetOs Granules to the gold standard of autograft bone.
Data from the prospective, multi-center, intra-patient-controlled trial showed a fusion rate for MagnetOs of 78%, compared to 42% for autograft. This compares favorably to fusion rates of 55-71% reported for other synthetic bone grafts evaluated in similar well-controlled studies of posterolateral fusion.1,2
The first consecutive 50 patients (from a total of 100) requiring up to four-level instrumented posterolateral lumbar fusion (T10 – S2), were included in this preliminary analysis. The rate of posterolateral lumbar/thoracolumbar fusion was assessed by CT-scan 12 months after surgery. Data can be downloaded from the Kuros website.
Joost de Bruijn, Chief Executive Officer of Kuros, said: “These interim results are truly exciting, exceeding our expectations for MagnetOs’ performance and validating our product as an augmented bone grafting option. Previous bone grafts have been sold on the premise of improved clinical outcomes based on data from the benchtop or preclinical setting alone. This study underlines Kuros’s commitment to a translational research approach through which we convert our ground-breaking research in the petri dish to Level I evidence of efficacy in humans, and as such is an important milestone in our Project Fusion global research program. It further demonstrates our commitment to fund research in the field of spine surgery for the benefit of patients, surgeons, and our wider society.”
The data will be used to support product approvals at hospitals and within hospital systems and will further support adoption of MagnetOs by surgeons who are looking for a reasonably priced augmented alternative to cell-based allografts, bone morphogenetic proteins and premium-priced synthetic bone grafts.
This interim data will be presented by Professor Sigurd Berven, Chief of Spine Service at University of California, San Francisco, at the 22nd Annual Meeting of the International Society for the Advancement of Spine Surgery (ISASS), taking place in the Bahamas, June 1-4, 2022.